Research progress on ferroptosis in Myelodysplastic syndromes DOI Creative Commons

Yifan Yang,

Jiongping Han,

Yanjun Wei

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 28, 2025

Myelodysplastic syndromes (MDS) are a group of malignancies characterized by clonal proliferation hematopoietic stem cells, ineffective hematopoiesis, peripheral cytopenias, and high risk transformation to acute myeloid leukemia. Current therapeutic strategies for MDS have limited efficacy. Thus, identifying new targets prognostic biomarkers is critical future research direction. Ferroptosis, type iron-dependent programmed cell death, has become recent hotspot in the field oncology research. Recent results demonstrated that iron metabolism, lipid other pathways can be targeted induce ferroptosis cells. In addition, ferroptosis-related genes significance prognosis diagnosis MDS. This article reviews current progress on MDS, including its potential targeting as intervention strategy.

Language: Английский

Monitoring Dynamic Changes of Cellular Membrane GSH During Stroke via an ESIPT-Based Near-Infrared Fluorescent Probe DOI Creative Commons
Yue Gao, Zhao Wang

Molecules, Journal Year: 2025, Volume and Issue: 30(3), P. 592 - 592

Published: Jan. 28, 2025

Stroke, primarily ischemic (85%), results from inadequate blood supply and is worsened by ferroptosis, characterized free radical generation lipid peroxidation. Monitoring ferroptosis essential for understanding its mechanisms developing treatments. Glutathione (GSH) a key biomarker, but current probes are limited short excitation/emission wavelengths, small Stokes shifts, inability to monitor dynamic GSH changes at the cellular membrane, where plays crucial role. To address these issues, we developed PM-Red-GSH, novel near-infrared (NIR) probe based on Excited-state intramolecular proton transfer (ESIPT) mechanism. It shows strong NIR emission (715 nm), large shift (290 enhanced membrane binding (PCC = 0.95) due alkyl group. PM-Red-GSH enables monitoring in an MCAO mouse model. These findings offer new insights into stroke treatment.

Language: Английский

Citations

0
Research progress on ferroptosis in Myelodysplastic syndromes DOI Creative Commons

Yifan Yang,

Jiongping Han,

Yanjun Wei

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 28, 2025

Myelodysplastic syndromes (MDS) are a group of malignancies characterized by clonal proliferation hematopoietic stem cells, ineffective hematopoiesis, peripheral cytopenias, and high risk transformation to acute myeloid leukemia. Current therapeutic strategies for MDS have limited efficacy. Thus, identifying new targets prognostic biomarkers is critical future research direction. Ferroptosis, type iron-dependent programmed cell death, has become recent hotspot in the field oncology research. Recent results demonstrated that iron metabolism, lipid other pathways can be targeted induce ferroptosis cells. In addition, ferroptosis-related genes significance prognosis diagnosis MDS. This article reviews current progress on MDS, including its potential targeting as intervention strategy.

Language: Английский

Citations

0